Johnson & Johnson (JNJ) announced on Tuesday that nipocalimab, its experimental therapy for an autoimmune condition called systemic lupus erythematosus, reached the main goal of a mid-stage trial.
Based on topline data, the New Brunswick, New Jersey-based pharma giant said that its Phase 2b JASMINE study met the primary endpoint related to a clinical measure called SLE Responder Index 4 over 24 weeks with a statistically significant impact.
According to the company, the FcRn blocker also met the key secondary and exploratory endpoints of JASMINE, which was designed to test nipocalimab in 228 adults with active SLE over 52 weeks.
Additionally, J&J (JNJ) noted that the experimental therapy demonstrated a safety and tolerability profile in line with prior trials and said that plans are underway to launch a Phase 3 program for nipocalimab in SLE based on JASMINE data.
The company expects to share the full trial results at a future medical event.